Skip to main content
. 2019 Aug 7;8(8):847. doi: 10.3390/cells8080847

Figure 1.

Figure 1

Association between the PyVAN-free survival and the HLA-E*01:03 carrier status of the transplant recipient during the first three years after living-donor kidney transplant. Recipients carrying the HLA-E*01:03 allelic variant were significantly more susceptible to develop PyVAN.